Market Overview

UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake

Share:
Related AEGR
Mid-Afternoon Market Update: Fed Leaves Rates Unchanged; Bob Evans Farms Shares Drop Following Weak Forecast
10 Biggest Mid-Day Gainers For Wednesday

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $37.00 to $41.00.

Deutsche Bank noted, “We also have higher conviction in peds-HOFH OPP'Y. However, we are removing FC OPP'Y from numbers on limited progress so far...Given that patient uptake has robust so far, we believe there could be upside to 2013 company guidance of $15-$25M in sales. We calculate that the company can generate $13M sales in 2013 with only these 85 pts added so far.”

Aegerion Pharmaceuticals closed on Tuesday at $34.47.

Latest Ratings for AEGR

DateFirmActionFromTo
Feb 2016Bank of AmericaDowngradesNeutralUnderperform
Dec 2015Guggenheim SecuritiesUpgradesSellBuy
Nov 2015Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (AEGR)

View Comments and Join the Discussion!